Endogenous Fe 2+ -triggered self-targeting nanomicelles for self-amplifying intracellular oxidative stress.

Self-targeting NMs represent a promising strategy for enhancing ASA-based treatments, leveraging clinically approved drugs to expedite drug development and clinical research in oncology.